Cargando…

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report

BACKGROUND: Emicizumab is a novel prophylactic medication used to treat patients with hemophilia A. It is indicated to minimize the frequency of bleeding episodes and the severity of serious bleeding in patients with hemophilia A utilizing inhibitors. However, some cases of bleeding episodes have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albattat, Sami, Alabdultaif, Abbas, Albattat, Fatimah, Albattat, Batla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948523/ https://www.ncbi.nlm.nih.gov/pubmed/36814352 http://dx.doi.org/10.1186/s13256-023-03783-7

Ejemplares similares

Pediatric Floating Elbow Caused by a Novel Mechanism: A Case Report
por: Albattat, Mustafa Y, et al.
Publicado: (2022)

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
por: Ahn, Ji Hyun, et al.
Publicado: (2021)

Disaster planning and preparedness in the hotel industry
por: Albattat, Ahmad Rasmi, et al.
Publicado: (2019)

On Event-Triggered Adaptive Architectures for Decentralized and Distributed Control of Large-Scale Modular Systems
por: Albattat, Ali, et al.
Publicado: (2016)

Knowledge, attitude, and barriers of seasonal influenza vaccination among pregnant women visiting primary healthcare centers in Al-Ahsa, Saudi Arabia. 2019/2020
por: Albattat, Huda Saleh, et al.
Publicado: (2021)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage
por: Yamada, Yuya, et al.
Publicado: (2022)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Non-inhibitory antibodies inducing increased emicizumab clearance in a severe hemophilia A inhibitor patient
por: Harroche, Annie, et al.
Publicado: (2021)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
por: Zhou, Zheng-Yi, et al.
Publicado: (2020)

Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
por: Yagyuu, Takahiro, et al.
Publicado: (2022)

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
por: Kizilocak, Hande, et al.
Publicado: (2019)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab
por: Inoue, Fumiya, et al.
Publicado: (2022)

Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
por: Al-Banaa, Kadhim, et al.
Publicado: (2019)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

A Rare Case of Intra-Articluar Osteoid Osteoma of the Elbow Managed With Arthroscopic Excision
por: Alrassasi, Yassin M, et al.
Publicado: (2021)

Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature
por: Kizilocak, Hande, et al.
Publicado: (2023)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
por: Rener, Karla, et al.
Publicado: (2023)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report
por: Guillaume, Louise, et al.
Publicado: (2021)

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
por: Kruse-Jarres, Rebecca, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
por: Warren, Beth Boulden, et al.
Publicado: (2021)

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
por: Iarossi, Michael, et al.
Publicado: (2022)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Management of children with hemophilia A on emicizumab who need surgery
por: Belletrutti, Mark, et al.
Publicado: (2023)

Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste
por: D’Albini, Lesley, et al.
Publicado: (2023)

Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor
por: Lefèvre, Charles R., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
por: Le Quellec, Sandra
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

PB2643: EFFICACY OF REDUCED-DOSE EMICIZUMAB IN HEMOPHILIA A WITH INHIBITORS: REAL WORLD EXPERIENCE IN MALAYSIA
por: Tang, Andy Sing Ong, et al.
Publicado: (2023)

Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile
por: Abarca-Villaseca, Viviana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pn2t5b5h33rvlhfh34d3odnq51